Analysis of CacyBP / SIP , ERK1 /2, and p38 Expression in Low‐ and High‐Grade Papillary Urothelial Carcinoma

Documenti analoghi

• Comparative Analysis of miRNA Expression 106a‐5p and 375‐3p and Proteins ERK1/2, p38, β‐Catenin and E‐Cadherin in Prostate Cancer and Benign Prostatic Hyperplasia
  di: Magdalena Smereczańska, et al.
  Pubblicazione: (2025)
• Genetic Alterations in Chromatin Regulatory Genes in Upper Tract Urothelial Carcinoma and Urothelial Bladder Cancer
  di: Shuo Wang, et al.
  Pubblicazione: (2024)
• Distinct Clinicopathological Features of HER2 ‐Negative, HER2 ‐Low, and HER2 ‐Overexpressing Urothelial Carcinoma in a Large Chinese Cohort
  di: Shanshan Wang, et al.
  Pubblicazione: (2025)
• Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
  di: Siming Li, et al.
  Pubblicazione: (2024)
• Treatment‐Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study
  di: Amanda Nizam, et al.
  Pubblicazione: (2025)